Nelson Van Denburg & Campbell Wealth Management Group LLC Purchases 3,153 Shares of Catalent, Inc. (NYSE:CTLT)

Posted by Defense World Staff on Jun 13th, 2023

Nelson Van Denburg & Campbell Wealth Management Group LLC raised its position in shares of Catalent, Inc. (NYSE:CTLT – Get Rating) by 40.6% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 10,916 shares of the company’s stock after acquiring an additional 3,153 shares during the quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC’s holdings in Catalent were worth $491,000 at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. Mitsubishi UFJ Trust & Banking Corp boosted its position in Catalent by 3.9% during the 4th quarter. Mitsubishi UFJ Trust & Banking Corp now owns 98,422 shares of the company’s stock valued at $4,430,000 after acquiring an additional 3,721 shares in the last quarter. Itau Unibanco Holding S.A. boosted its position in shares of Catalent by 372.7% in the 3rd quarter. Itau Unibanco Holding S.A. now owns 3,134 shares of the company’s stock worth $227,000 after purchasing an additional 2,471 shares in the last quarter. Inspire Investing LLC boosted its position in shares of Catalent by 12.1% in the 4th quarter. Inspire Investing LLC now owns 25,647 shares of the company’s stock worth $1,154,000 after purchasing an additional 2,775 shares in the last quarter. Tower Research Capital LLC TRC boosted its position in shares of Catalent by 313.9% in the 3rd quarter. Tower Research Capital LLC TRC now owns 49,717 shares of the company’s stock worth $3,597,000 after purchasing an additional 37,706 shares in the last quarter. Finally, Park Avenue Securities LLC boosted its position in shares of Catalent by 15.6% in the 4th quarter. Park Avenue Securities LLC now owns 12,422 shares of the company’s stock worth $559,000 after purchasing an additional 1,673 shares in the last quarter. 99.38% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, SVP Mario Gargiulo sold 678 shares of the company’s stock in a transaction on Monday, May 1st. The shares were sold at an average price of $49.86, for a total value of $33,805.08. Following the completion of the transaction, the senior vice president now owns 5,676 shares of the company’s stock, valued at approximately $283,005.36. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In other Catalent news, SVP Mario Gargiulo sold 678 shares of the stock in a transaction dated Monday, May 1st. The shares were sold at an average price of $49.86, for a total transaction of $33,805.08. Following the completion of the transaction, the senior vice president now owns 5,676 shares of the company’s stock, valued at approximately $283,005.36. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Manja Boerman sold 1,446 shares of the stock in a transaction dated Monday, May 1st. The shares were sold at an average price of $49.86, for a total transaction of $72,097.56. Following the transaction, the insider now directly owns 14,414 shares of the company’s stock, valued at approximately $718,682.04. The disclosure for this sale can be found here. 0.58% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

CTLT has been the topic of a number of analyst reports. Royal Bank of Canada dropped their price target on Catalent from $58.00 to $41.00 in a research report on Monday, May 8th. Morgan Stanley lowered their price objective on Catalent from $85.00 to $50.00 in a research report on Monday, May 22nd. Bank of America lowered shares of Catalent from a “neutral” rating to an “underperform” rating and set a $28.00 target price for the company. in a research note on Monday, May 8th. JPMorgan Chase & Co. lowered shares of Catalent from an “overweight” rating to a “neutral” rating and decreased their target price for the company from $90.00 to $45.00 in a research note on Sunday, May 21st. Finally, Barclays boosted their target price on shares of Catalent from $35.00 to $42.00 in a research note on Monday. Two analysts have rated the stock with a sell rating, six have assigned a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat, Catalent presently has an average rating of “Hold” and an average target price of $68.18.

Catalent Trading Up 10.3 %

Shares of Catalent stock opened at $42.80 on Tuesday. The company has a market capitalization of $7.71 billion, a P/E ratio of 18.94, a P/E/G ratio of 5.83 and a beta of 1.18. The company has a debt-to-equity ratio of 0.86, a quick ratio of 1.38 and a current ratio of 1.91. The company has a fifty day moving average of $44.01 and a 200 day moving average of $52.48. Catalent, Inc. has a fifty-two week low of $31.45 and a fifty-two week high of $115.33.

Catalent Company Profile

(Get Rating)

Catalent, Inc is a holding company, which engages in the provision of delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. It operates through the following segments: Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services.